---
schema_version: "secwatch.filing_event.v1"
accession: "0001387131-22-010041"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2022-09-28T23:59:59+00:00"
generated_at: "2026-06-23T06:58:37.003528+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences appoints Kevin Danahy as CEO; grants 450,000 share option

## Summary
- Kevin Danahy, previously Chief Commercial Officer, named CEO effective September 20, 2022.
- Annual base salary of $400,000 and target bonus up to 100% of base salary.
- Received option to acquire 450,000 shares vesting over 4 years at closing price on grant date.
- Amended employment agreement includes 24-month severance if terminated within 2 years.
- Danahy brings 20+ years medtech experience from Intuitive Surgical, Zimmer Biomet, Medtronic.

## SEC filing metadata
- accession: 0001387131-22-010041
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2022-09-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000138713122010041/0001387131-22-010041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000138713122010041/pulse-8k_092322.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001387131-22-010041
- JSON: https://secwatch.observer/filing/0001387131-22-010041.json
- Plain text: https://secwatch.observer/filing/0001387131-22-010041.txt

## Key facts
- Executive change
  Kevin Danahy was appointed as Chief Executive Officer at PULSE BIOSCIENCES, INC..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On September 23, 2022, in connection with the appointment of Kevin Danahy as Chief Executive Officer of Pulse Biosciences, Inc. (the “Company”), Mr. Danahy and the Company entered into an amendment (the “Danahy Amendment”) to Mr. Danahy’s employment agreement, dated February 9, 2022, which was initially entered into in connection with his appointment as Chief Commercial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1625101/000138713122010041/0001387131-22-010041-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.